SB-913
Regenxbio’s investigational gene therapy shows promise in Hunter syndrome
The rare genetic disease is estimated to affect one in every 100,000 to 170,000 births
Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration
The companies will develop CRISPR-based therapies for neurological and muscular diseases
Moderna and Life Edit partner to accelerate gene editing therapies
The companies will jointly develop in vivo mRNA therapies for hard-to-treat diseases
New T-cell study demonstrates ‘powerful’ potential for tailored cancer medicine
The results were published in a peer-reviewed paper in Nature
Disrupting Cell Engineering with Non-Viral Modalities
Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing...
Scribe Therapeutics continues to advance the development of its CRISPR platform and pipeline
Company was co-founded by Jennifer Doudna, a co-inventor of CRISPR technology
Gene Editing and Precision Medicine: The Future of Healthcare?
Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,...
Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal
Gains rights to tau-targeting drug ST-501 as part of broader alliance
Sangamo steps up BioMarin chase with haemophilia gene therapy data
Updated results presented at ASH 2019
Vertex reveals promising data from first CRISPR-treated patients
Investigational gene therapy has potentially curative effect
New results back Sangamo, UniQure haemophilia gene therapies
Encouraging results for firms in four-way race
